Orchid Pharma Limited · NSE:ORCHPHARMA
Orchid Pharma — Investor Presentation (June 2021)
21 slides from Orchid Pharma's investor presentation, Jun 9, 2021
Slide 1: Orchid Pharma Corporate Presentation Cover Letter
OrchidPharmaY ( Formerly known as Orchid Chemicals & Pharmaceuticals Limited } Corp. Off.: Orchid Pharma Ltd., ‘Orchid Towers’ 313, Valluvarkottam High Road, Nungambakkam, Chennai - 600 034. India CIN: L24222TN1992PLC022994 June 09, 2021 National Stock Exchange of India Ltd BSE Limited Listing Depar
Slide 2: The Turnaround Story
OrchidPharma? — A Dhanuka Group Company — The Turnaround Story
Slide 3: Company Overview
OrchidPharma? — A Dhanuka Group Company — COMPANY OVERVIEW PIONEER IN CEPHALOSPORIN ANTIBIOTICS R&D Focused, Inventor of Enmetazobactam (Ph.-3 Trials done in US & EU) Acquired by Dhanuka Group through CIRP Process on Ist April 2020 ABOUT DHANUKA GROUP ~ 2500 Crore diversified group. interests in Cro
Slide 4: Orchid history timeline
OrchidPharma? — A Dhanuka Group Company — -e®@ e @e- @ 1992 ( @ 2015 Orchid was Formed Goes into CDR ) 2017 @ 2005 Admitted to IBC First USFDA Approval FDF Facility Inaugurated by Dr. APJ Abdul Kalam 0 2018 @ 2008 First resolution plan fails First ANDA Approval Partnership with Merck for Drug Discov
Slide 5: Dhanuka Group companies
ities! OrchidPharma¥ TWorcoleeu hens: DHANUKA AGRITECH LTD DHANUKA LABORATORIES LTD. es! ee! * Flagship of the Group founded in 1980. * Pharmaceutical Arm started in 1998. * Listed on Stock Exchanges for 35 years with a Market « Leader in Cephalosporin Antibiotics in Emerging markets. Cap of USD 600
Slide 6: Key Rationale for Acquiring Orchid Pharma
OrchidPharma¥ — A Dhanuka Group Company — KEY RATIONALE FOR ACQUIRING ORCHID PHARMA -e®@ e @e- ORCHID DHANUKA GROUP Strengths Strengths 1. Regulatory Agency approvals — US 1. Cost Efficient Management 2. Large Capacity 3. Execution Capabilities 3. Widest Range Threats S Weaknesses S 1. High Cost Thr
Slide 7: Antibiotics: The Life Saving Drugs
OrchidPharma? — A Dhanuka Group Company — ANTIBIOTICS GLOBAL ANTIBIOTICS MARKET SHARE, BY DRUGS CLASS,2019 THE LIFE SAVING DRUGS Cephalosporin Penicillin > Global Antibiotics Market in 2019 — USD 43 bn Fluoroquinolone Macrolides Others Cephs have Excellent Safety profile and wide > coverage of gram-
Slide 8: Capabilities
OrchidPharma? — A Dhanuka Group Co CAPABILITIES
Slide 9: Widest Range of Cephalosporins
OrchidPharma¥ — A Dhanuka Group Company — WIDEST RANGE OF CEPHALOSPORINS Under Development products ORAL Cefadroxil ORAL Cefalexin Cefprozil ORAL Cefradine Cefuroxime Cefdinir Cefditoren STERILE STERILE Cefixime Cefepime Cefalonium STERILE Cefpodoxime Cefpirome Cefalothin Cefquinome STERILE Cefoxiti
Slide 10: Global Presence with a Wide Customer Base
OrchidPharma? — A Dhanuka Group Company — GLOBAL PRESENCE WITH A WIDE CUSTOMER BASE ORCHID’S PRESENCE SANDOZ (ii) Mylan’ KUKJEPHARMA K Antibiotice hikma. = Pfizer ™ 7) ‘polpharma @ Otsuka Momenta a SANOFI wy STADA So PHARMA 4% 5% 2% 6% & & 3 wv B Africa Asia Africa BASIC m Europe m Europe m North Am
Slide 11: Largest Integrated Cephalosporin API Company
{Pharma¥ LARGEST INTEGRATED CEPHALOSPORIN API COMPANY ¢ Integrated facilities from Intermediate to finished — 60 Acre Sterile — 3 Lines Sterile Crystalline and 1 Lyophilized ¢ Oral —-7 Blocks with multiple lines * Intermediates — 5 Blocks with multiple lines * Total Capacity 9OOMT ¢ Worldwide approv
Slide 12: Finished Dosage Facilities
OrchidPharma? — A Dhanuka Group Company — FINISHED DOSAGE FACILITIES IKKT ¢ USFDA / UKMHRA Certified ¢ 29 ANDAs with associated DMFs ¢ Exporting to US / EU Markets ¢ Now Hived off to associate JV Company FI ¢ Was a small Cephalosporin Operation « Now being upgraded to meet PICS standards ¢ Will focu
Slide 13: Strong R&D Capabilities
OrchidPharma? — A Dhanuka Group Company — STRONG R&D CAPABILITIES ANALYTICAL R&D PROCESS R&D NMR (Multinuclear) Sterile Crystallization & Lyophilization Powder XRD ICPMS Asymmetric Synthesis LCMS/MS Chemical Resolution lon Chromatograph Preparative HPLC Enzymatic Catalysis Freeze Driers Amino acids
Slide 14: Board of Directors
OrchidPharma? — A Dhanuka Group Company — BOARD OF DIRECTORS BOARD OF DIRECTORS Mr. Ram Gopal Agarwal Mr. Manish Dhanuka Mr. Arun Kumar Dhanuka Mr. Mridul Dhanuka Chairman and Non- Managing Director Non-Executive Director Whole-Time Director Executive Director ~Visionary Leader at the ~Director at D
Slide 15: Focus on ESG
OrchidPharma? — A Dhanuka Group Company — FOCUS ON ESG Environment Consciousness has been Orchid’s 01. Hallmark right from Inception. Orchid now backed by Dhanuka group, having 02 excellent Corporate Governance Standards Dupont safety systems implemented with an aim 03 TARA of Zero Incident ORCHID’S
Slide 16: Commitment to Environment
OrchidPharma? — A Dhanuka Group Company — COMMITMENT TO ENVIRONMENT * Advanced Evaporation and RO Systems - Vent Gas Scrubbing System * ZERO Liquid Discharge ¢ Highest Possible Recovery @ -80deg Centigrade ¢ No fugitive Emissions ¢ 70% of fresh Water is recycled after recovery » ESP / Venturi Filter
Slide 17: Future Strategy
OrchidPharma? — A Dhanuka Group Company — FUTURE STRATEGY
Slide 18: Strategy for Orchid API Business
OrchidPharma¥ — A Dhanuka Group Company — STRATEGY FOR ORCHID API BUSINESS WIN BACK LOST BUSINESS WIN BACK LOST BUSINESS WIN BACK LOST BUSINESS ¢ Bring down term debt to below * ORAL *- To develop new products, which Rs. 100 crore by March 2022 ¢ Target old customers in are already off patent, but n
Slide 19: Strategy - To Attain Leadership in APIs
OrchidPharma¥ — A Dhanuka Group Company — STRATEGY - TO ATTAIN LEADERSHIP IN APIS Business Consolidation Committee formed to evaluate the consolidation of Dhanuka Laboratories Limited with Orchid. PROPOSAL TO CONSOLIDATE GROUP’S API This consolidation was part of the Resolution Plan submitted to NCL
Slide 20: Proud Moment for India: Enmetazobactam Clears Phase 3
OrchidPharma¥ — A Dhanuka Group Company — PROUD MOMENT FOR INDIA FIRST PRODUCT INVENTED IN INDIA, TO CLEAR PH.-3-ENMETAZOBACTUM In 2013, Orchid out licensed a NCE Enmetazobactum to Allecra Therapeutics, Germany for Clinical Trials. Cleared the Phase 3 trials in October 2020. This is a Unique Beta La
Slide 21: Financials
OrchidPharma? — A Dhanuka Group Co FINANCIALS